Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control

Background: In individuals with a low diastolic blood pressure (DBP), the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear. Methods: SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized controlled trial that compared the effects of intensive (target <120 mm Hg) and standard (target <140 mm Hg) SBP control in 9361 older adults with high blood pressure at increased risk of cardiovascular disease. The primary outcome was a composite of cardiovascular disease events. All-cause death and incident chronic kidney disease were secondary outcomes. This post hoc analysis examined whether the effects of the SBP intervention differed by baseline DBP. Results: Mean baseline SBP and DBP were 139.7±15.6 and 78.1±11.9 mm Hg, respectively. Regardless of the randomized treatment, baseline DBP had a U-shaped association with the hazard of the primary cardiovascular disease outcome. However, the effects of the intensive SBP intervention on the primary outcome were not influenced by baseline DBP level (P for interaction=0.83). The primary outcome hazard ratio for intensive versus standard treatment was 0.78 (95% confidence interval, 0.57–1.07) in the lowest DBP quintile (mean baseline DBP, 61±5 mm Hg) and 0.74 (95% confidence interval, 0.61–0.90) in the upper 4 DBP quintiles (mean baseline DBP, 82±9 mm Hg), with an interaction P value of 0.78. Results were similar for all-cause death and kidney events. Conclusions: Low baseline DBP was associated with increased risk of cardiovascular disease events, but there was no evidence that the benefit of the intensive SBP lowering differed by baseline DBP. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01206062.

[1]  Deepak L. Bhatt,et al.  Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study , 2016, The Lancet.

[2]  J. Coresh,et al.  60 A comparison of HFrEF vs HFpEF’s clinical workload and cost in the first year following hospitalisation and enrollment in a disease management program , 2016, Journal of the American College of Cardiology.

[3]  Lenore J Launer,et al.  Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. , 2016, JAMA.

[4]  Ji-Guang Wang,et al.  The J-Curve Phenomenon in Hypertension , 2016, Pulse.

[5]  M. Woodward,et al.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.

[6]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[7]  K. Kalantar-Zadeh,et al.  Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. , 2014, Journal of the American College of Cardiology.

[8]  Walter T Ambrosius,et al.  The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT) , 2014, Clinical trials.

[9]  Harry Hemingway,et al.  Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people , 2014, The Lancet.

[10]  Mahboob Rahman,et al.  Limitations of Analyses Based on Achieved Blood Pressure: Lessons From the African American Study of Kidney Disease and Hypertension Trial , 2011, Hypertension.

[11]  S. Bangalore,et al.  J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. , 2010, European heart journal.

[12]  N J Wald,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[13]  H. Ueshima,et al.  Relation of Blood Pressure and All-Cause Mortality in 180 000 Japanese Participants: Pooled Analysis of 13 Cohort Studies , 2008, Hypertension.

[14]  M. Pencina,et al.  General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study , 2008, Circulation.

[15]  W. Elliott On-Treatment Diastolic Blood Pressure and Prognosis in Systolic Hypertension , 2008 .

[16]  Gina Soriya,et al.  Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? , 2007 .

[17]  C. McCulloch,et al.  Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. , 2005, Archives of internal medicine.

[18]  S. Lewington Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002) , 2003 .

[19]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[20]  W. Cushman,et al.  The role of diastolic blood pressure when treating isolated systolic hypertension. , 1999, Archives of internal medicine.

[21]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[22]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[23]  P. Whelton,et al.  Blood pressure and end-stage renal disease in men. , 1996, The New England journal of medicine.

[24]  C. Mulrow,et al.  The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? , 1991, JAMA.

[25]  J. Cruickshank,et al.  BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE , 1987, The Lancet.